Jinghua Pharmaceutical Group (SHE:002349) subsidiary Jinghua Nantong obtained the approval of China's medical products administrator to market its Ritonavir active pharmaceutical ingredient.
The API is used in HIV/AIDS treatment and in COVID-19 therapies, according to a filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 1% lower Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.